文献速递前列腺癌

达罗他胺联合ADT治疗mHSPC按疾病体积与风险分层的ARANOTE试验事后分析

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.
PubMed 文献 · Eur Urol · 2026-08-12

ARANOTE试验事后分析按CHAARTED和LATITUDE标准将669例mHSPC患者分为高/低体积和高/低风险亚组,评估达罗他胺联合ADT的疗效与安全性。结果显示,各亚组的影像学无进展生存期(rPFS)均较安慰剂联合ADT显著改善,且治疗中出现的不良事件两组相似。

要点

  • 达罗他胺联合ADT在各疾病体积/风险亚组均改善rPFS。
  • 高体积、低体积、高风险、低风险亚组的rPFS风险比分别为0.60、0.30、0.61、0.40。
  • 各亚组治疗中出现的不良事件与安慰剂联合ADT相似。

核心结论

  • 无论疾病体积或风险如何,达罗他胺联合ADT均较安慰剂联合ADT改善结局且耐受性良好。

研究设计与样本

  • ARANOTE(NCT04736199)3期随机试验的事后分析,669例mHSPC患者按2:1随机接受达罗他胺联合ADT或安慰剂联合ADT。
  • 高体积和低体积按CHAARTED标准定义,高风险和低风险按LATITUDE标准定义。

主要发现

  • 高体积亚组472例,rPFS风险降低40%(HR 0.60,95%CI 0.44-0.80)。
  • 低体积亚组197例,rPFS风险降低70%(HR 0.30,95%CI 0.15-0.60)。
  • 高风险亚组400例,rPFS风险降低39%(HR 0.61,95%CI 0.44-0.86)。
  • 低风险亚组269例,rPFS风险降低60%(HR 0.40,95%CI 0.25-0.62)。
  • 所有次要终点在各亚组中均显示与安慰剂相似的改善趋势,治疗中出现的不良事件两组相似。

关键数值与推荐

  • rPFS为主要终点,其他终点包括至后续系统抗癌治疗时间、至mCRPC时间、至PSA进展时间、至疼痛进展时间、PSA<0.2 ng/ml率、总生存期和安全性。

临床怎么用

  • 达罗他胺联合ADT可作为mHSPC患者的治疗选择,不受疾病体积或风险分层限制。

局限性

  • 为事后分析,亚组结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In ARANOTE (NCT04736199), darolutamide plus androgen-deprivation therapy (ADT) significantly reduced the risk of radiologic progression or death versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, with favorable safety. Here, we report on post hoc outcomes by disease volume/risk. Randomized patients received darolutamide plus ADT or placebo plus ADT (2:1). High-volume (HV) and high-risk (HR) disease were defined by the CHAARTED and LATITUDE criteria, respectively. End points included radiologic progression-free survival (primary; rPFS), time to initiation of subsequent systemic anticancer therapy, time to metastatic castration-resistant prostate cancer, time to prostate-specific antigen (PSA) progression, time to pain progression, PSA <0.2 ng/ml rates, overall survival, and safety. Of 669 patients, 472 had HV disease, 197 had low-volume (LV) disease, 400 had HR disease, and 269 had low-risk (LR) disease; baseline characteristics were generally balanced. Darolutamide consistently reduced the rPFS (HV: 40% [hazard ratio, 0.60; 95% confidence interval, 0.44 to 0.80]; LV: 70% [0.30; 0.15 to 0.60]; HR: 39% [0.61; 0.44 to 0.86]; LR: 60% [0.40; 0.25 to 0.62]), with similar trends for all secondary end points versus placebo. Treatment-emergent adverse events were similar between treatment arms across all subgroups. Darolutamide was well tolerated, and outcomes were improved versus placebo, regardless of disease volume/risk. Prior presentation: Presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, San Francisco, CA, February 13-15, 2025. Clinical trial registration: NCT04736199 (EudraCT 2020-003093-48).

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Saad F, Shore N, Vjaters E, et al. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026. PMID: 42586872. doi:10.1016/j.eururo.2026.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。